NCT02049593 2022-09-26
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
Sanofi
Gustave Roussy, Cancer Campus, Grand Paris